Ryght uses AI Site Twin technology—digital models of every clinical research site in the world. When biopharma or CRO clients input a study protocol, our advanced AI and machine learning algorithms instantly analyze it and scan our network of 100,000+ AI Site Twins to identify optimal site matches. Each AI Site Twin captures a site's unique operational characteristics, historical trial performance, and patient populations, and is constantly updated in real-time data.

Once optimal sites are identified, Ryght's Feasibility Accelerator automatically sends qualified sites pre-populated feasibility questionnaires powered by their AI Site Twin data. Sites only need to review and confirm responses—reducing traditional 4-6 week feasibility cycles to just days. Sponsors and CROs can track and compare all responses in real-time and optimize throughout the trial, compressing traditional 6-12 month processes into weeks.

For Sites:
Clinical research sites can access Ryght's AI-powered Feasibility platform and other tools completely free. The platform helps those sites save time on feasibility assessments with pre-populated questionnaires. We also offer tools to match patients across protocols in seconds, and quickly navigate complex visit schedules. 

For Sponsors:
 Biopharma sponsors can use Ryght to maintain complete strategic control over site selection, reduce dependency on external teams, and compress development timelines by 6-12 months per study. The platform provides direct access to site identification, feasibility management, and performance optimization.

Ryght's AI Site Twins are built on comprehensive data about each site's operational characteristics, historical trial performance, and patient populations. Our AI retriever agents continuously update every twin with real-time data from public and other sources, ensuring the information reflects current conditions. The platform uses advanced AI and machine learning algorithms to analyze complex datasets and identify patterns, providing predictive capabilities that enable more informed decision-making throughout the site selection and feasibility process.

Feasibility is free for sites. Biopharma sponsors and CROs pay a subscription. To find out more, book a demo. 

Comprehensive AI Site Twin Network: Access to digital replicas of 100,000+ clinical research sites globally, providing unprecedented reach and depth of site intelligence
Speed: Cut months of manual research down to minutes with instant protocol analysis and site matching
Dynamic Real-Time Data: AI retriever agents constantly update site information, unlike static databases that quickly become outdated
End-to-End Platform: Integrated solution covering site identification, feasibility acceleration, and ongoing study optimization—not just isolated point solutions
Pre-Populated Feasibility: Questionnaires come pre-filled with AI Site Twin data, reducing response times from weeks to days
Cost Elimination: Eliminates the need for expensive database subscriptions and reduces manual labor costs
Proven ROI: Demonstrable impact on timelines, costs, and study success rates

Current system status and historical uptime can be verified at https://status.ryght.ai. 

Contact support@ryght.ai for additional assistance with any issues you're experiencing.

Ryght uses the collected information for various purposes. This includes providing, maintaining, and improving their services, personalizing the user experience, analyzing user behavior, developing new products and features, communicating with users, facilitating third-party services, marketing and advertising, generating anonymized data, and ensuring compliance with legal obligations.

Users have certain choices regarding their information. They can prevent the sharing of precise location information on their devices, unsubscribe from promotional emails, and exercise their European privacy rights. These rights include requesting access to information, updating and correcting inaccuracies, restricting or objecting to processing, anonymizing or deleting information, and data portability. Users may also block cookies, although it may affect the functionality of the services.

Ryght takes measures to delete or anonymize information when it's no longer necessary for the purposes of processing. Retention periods are determined based on various factors, and may be specific to your enterprise agreement with us. Ryght employs physical and electronic safeguards to improve the security of the information they maintain but acknowledges that no system is entirely secure.